查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1302166

癌症/腫瘤分析市場：按技術、按生物標記類型、按癌症類型、按用途- 俄羅斯-烏克蘭衝突、高通貨膨脹的累積影響 - 2023-2030 年全球預測

Cancer/Tumor Profiling Market by Technology, Biomarker Type, Cancer Type, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球癌症/腫瘤分析市場預計到 2023 年將大幅成長，達到 107.9854 億美元，複合年成長率為 18.67%，到 2030 年將達到 359.4438 億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球癌症/腫瘤分析市場至關重要。通過檢查業務戰略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的具體需求做出明智的資訊。這種高級分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、積累和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通貨膨脹的累積影響。

5、競爭評估與資訊：對主要企業的市場佔有率、戰略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評價。

6. 產品開發和創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.癌症/腫瘤分析的全球市場規模和預測是多少？

2.在預測期內，COVID-19 對全球癌症/腫瘤分析市場的抑制要素和影響是什麼？

3. 在預測期內，全球癌症/腫瘤分析市場需要投資哪些產品/細分市場/應用/領域？

4. 全球癌症/腫瘤分析市場的競爭策略是什麼？

5.全球癌症/腫瘤分析市場的技術趨勢和法律規範是什麼？

6.全球癌症/腫瘤分析市場主要供應商的市場佔有率是多少？

7. 哪些型態和戰略舉措被認為適合進入全球癌症/腫瘤分析市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 在癌症患者的治療中更多地採用生物標記
      • 政府和全球組織努力設計癌症診斷方法的可用性
      • 對癌症治療個人化醫療的興趣激增
    • 抑制因素
      • 對癌症/腫瘤分析產品和服務的大量資本投資
    • 機會
      • 下一代測序的出現和腫瘤分析的進展
      • 改進現場診斷技術以改善癌症檢測
    • 課題
      • 生物標記的發現和批准率較低
  • 市場趨勢
    • 隨著癌症/腫瘤分析解決方案的快速進步，政府的癌症診斷舉措
    • 隨著癌症監測工作的發展，癌症罹患率不斷上升，增加了亞太地區對新癌症/腫瘤分析的需求
    • 擴大精準醫療和基因分析解決方案的部署，以克服整個歐洲、中東和非洲地區的癌症負擔
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通貨膨脹的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 癌症/腫瘤分析市場：按技術分類

  • 免疫測定法
  • 原位雜合技術
  • 質譜
  • 微陣列
  • 下一代測序
  • 聚合酶鍊式反應

第7章 按生物標記類型分類的癌症/腫瘤分析市場

  • 基因組生物標記
  • 蛋白質生物標記

第8章 按癌症類型分類的癌症/腫瘤分析市場

  • 乳腺癌
  • 結直腸癌
  • 肺癌
  • 黑色素瘤癌症
  • 前列腺癌

第9章 癌症/腫瘤分析市場：按用途

  • 生物標記發現
  • 臨床應用
  • 診斷
  • 個人化醫療
  • 預後
  • 調查
  • 篩分
  • 治療和監測

第10章 美洲癌症/腫瘤分析市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太癌症/腫瘤分析市場

  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲癌症/腫瘤分析市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 競爭情景分析：主要企業
    • 合併_
    • 契約、合作和夥伴關係
    • 新產品發布和功能增強
    • 投資、資金籌措
    • 獎項/表彰/擴展

第14章上市公司名單

第15章附錄

  • 討論指南
  • 關於許可和定價
Product Code: MRR-374DB5A06C9C

The Global Cancer/Tumor Profiling Market is forecasted to grow significantly, with a projected USD 10,798.54 million in 2023 at a CAGR of 18.67% and expected to reach a staggering USD 35,944.38 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer/Tumor Profiling Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer/Tumor Profiling Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Technology, market is studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, and Polymerase Chain Reaction. The Next-Generation Sequencing commanded largest market share of 24.12% in 2022, followed by Immunoassays.

Based on Biomarker Type, market is studied across Genomic Biomarker and Protein Biomarker. The Genomic Biomarker commanded largest market share of 58.77% in 2022, followed by Protein Biomarker.

Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, and Prostate Cancer. The Lung Cancer commanded largest market share of 23.23% in 2022, followed by Breast Cancer.

Based on Application, market is studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring. The Diagnostics commanded largest market share of 22.12% in 2022, followed by Personalized Medicine.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.45% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer/Tumor Profiling Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer/Tumor Profiling Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer/Tumor Profiling Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer/Tumor Profiling Market?

4. What is the competitive strategic window for opportunities in the Global Cancer/Tumor Profiling Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer/Tumor Profiling Market?

6. What is the market share of the leading vendors in the Global Cancer/Tumor Profiling Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer/Tumor Profiling Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer/Tumor Profiling Market, by Technology, 2022 vs 2030
  • 4.3. Cancer/Tumor Profiling Market, by Biomarker Type, 2022 vs 2030
  • 4.4. Cancer/Tumor Profiling Market, by Cancer Type, 2022 vs 2030
  • 4.5. Cancer/Tumor Profiling Market, by Application, 2022 vs 2030
  • 4.6. Cancer/Tumor Profiling Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
      • 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
      • 5.1.1.3. Surging preference for personalized medicines for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
      • 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
    • 5.1.4. Challenges
      • 5.1.4.1. Low biomarker discovery-to-approval ratio
  • 5.2. Market Trends
    • 5.2.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
    • 5.2.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
    • 5.2.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Cancer/Tumor Profiling Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunoassays
  • 6.3. In-Situ Hybridization
  • 6.4. Mass Spectrometry
  • 6.5. Microarrays
  • 6.6. Next-Generation Sequencing
  • 6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Genomic Biomarker
  • 7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Colorectal Cancer
  • 8.4. Lung Cancer
  • 8.5. Melanoma Cancer
  • 8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

  • 9.1. Introduction
  • 9.2. Biomarker Discovery
  • 9.3. Clinical Application
  • 9.4. Diagnostics
  • 9.5. Personalized Medicine
  • 9.6. Prognostics
  • 9.7. Research
  • 9.8. Screening
  • 9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player
    • 13.3.1. Merger & Acquisition
      • 13.3.1.1. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
      • 13.3.1.2. Prenetics Acquires ACT Genomics
    • 13.3.2. Agreement, Collaboration, & Partnership
      • 13.3.2.1. Sophia Genetics, Agilent Partner on Cancer Analysis Product
      • 13.3.2.2. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
    • 13.3.3. New Product Launch & Enhancement
      • 13.3.3.1. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
      • 13.3.3.2. ​​Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
    • 13.3.4. Investment & Funding
      • 13.3.4.1. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
      • 13.3.4.2. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals
    • 13.3.5. Award, Recognition, & Expansion
      • 13.3.5.1. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
      • 13.3.5.2. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
  • FIGURE 5. CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2022 VS 2030 (%)
  • FIGURE 6. CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
  • FIGURE 7. CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 8. CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. CANCER/TUMOR PROFILING MARKET DYNAMICS
  • FIGURE 10. CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 198. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 199. CANCER/TUMOR PROFILING MARKET LICENSE & PRICING